About
Remedee Labs, a French start-up that is part of Future4care’s accelerator program, has developed and refined the first non-invasive neuromodulation solution that revolutionizes chronic pain management. In December 2022, the company has entered in a partnership with Generali France, providing Remedee Labs with the resources to accelerate the commercialization of its solution both domestically and abroad. Additionally, the partnership enables Remedee Labs to continue to advance its neuromodulation technology and broaden its range of services.
Innovation presentation
To improve the quality of life of the 1.5 billion people worldwide suffering from chronic pain, Remedee Labs has developed and patented the first individual endorphin stimulator based on millimetre waves. This innovative bracelet is connected, easy to use, and helps stimulate the body’s naturel painkillers to provide long-term relief.
However, improving the quality of life of chronic pain patients requires an integrated approach that addresses all aspects of a person’s well-being. Therefore, Remedee Labs has also developed a comprehensive service around the bracelet that includes personalized support from health coaches, a digital service platform, and real-life data to attest to the solution’s effectiveness.
Generali, a leading insurance company, has recognized the potential of Remedee Lab’s solution and became a strategic partner of the start-up by taking a stake in its capital in 2022. Together, they have initiated three concrete projects, including testing the solution with Generali employees, offering the solution to 300,000 beneficiaries of the Health and Provident social action, and combining Remedee Lab’s medical data and Generali’s insurance data to demonstrate the reduction in claims allowed by the solution.
In France, at least 12 million people suffer from chronic pain, and 70% of them do not receive appropriate treatment, severly impacting their quality of life. Remedee Labs’ solution offers hope for those who have been failed by traditional treatments and can improve their quality of life in the long term.
Uniqueness of the project
The Remedee Labs solution is innovative in several aspects. Firstly, it utilizes millimeter wave stimulation to release endorphins, which is a patented technology with no equivalent on the market. Secondly, the connected bracelet is extremely user-friendly, ease to use anywhere and anytime, and has a sleek, non-stigmatizing design unlike most pain management devices. Thirdly, it employs a “bio-psycho-social” approach, combining technology with personalized human support and a digital service platform. Fourthly, Remedee Labs generates real-life data to measure the solution’s impact on health, quality of life, consumption of care, and absenteeism. Finally, Remedee Labs is conducting extensive clinical studies in fibromyalgia, which affect 14 million people in Europe and has no effective treatment to date, thus providing an opportunity to become the first validated solution to improve the health of fibromyalgia patients in Europe.
The Remedee Labs – Generali partnership also has several innovative aspects. Firstly, it enables the large-scale availability of this major innovation to policyholders, notably through Generali’s social action fund and its alliance with Klesia. Secondly, the partnership aims to establish a unique proof of impact and RoI (Return on Investment) by combining Remedee Labs’ medical data witch Generali’s insurance data, which is unprecedented in the social protection market.
